Package Leaflet: Information for the User
Enalapril Tarbis 20 mg Tablets EFG
Enalapril Maleate
Read this leaflet carefully before you start to take this medicine because it contains important information for you.
Enalapril Tarbis belongs to a group of medicines called angiotensin-converting enzyme inhibitors (ACE inhibitors).
Enalapril Tarbis is indicated for:
Do not take Enalapril Tarbis
Warnings and precautions
Consult your doctor or pharmacist before starting to take Enalapril Tarbis
Your doctor may monitor your renal function, blood pressure, and electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Enalapril Tarbis”.
You should inform your doctor if you think you may be pregnant (or could be). Enalapril Tarbis is not recommended at the beginning of pregnancy and should not be taken if you are more than 3 months pregnant, as it can cause serious harm to your baby if used in this stage (see Pregnancy section).
You should be aware that Enalapril Tarbis reduces blood pressure in black patients less effectively than in patients who are not black.
In all these cases, inform your doctor as you may need a dose adjustment or discontinue Enalapril Tarbis or monitor your potassium levels in the blood. If you have diabetes and are taking oral antidiabetic medications or insulin, you should closely monitor your blood glucose levels, especially during the first month of treatment with Enalapril Tarbis.
Inform your doctor or dentist before undergoing surgery or anesthesia (even at the dentist's office), as there may be a sudden drop in blood pressure associated with anesthesia.
Taking Enalapril Tarbis with other medications
Inform your doctor or pharmacist if you are using, have used recently, or may need to use any other medication.
Certain medications may interact with Enalapril Tarbis. Your doctor may need to adjust your dose and/or take other precautions, such as discontinuing one of them.
Particularly, talk to your doctor or pharmacist if you are taking, have taken recently, or may need to take any of the following medications:
Taking Enalapril Tarbis with food, drinks, and alcohol
Food does not affect the absorption of Enalapril Tarbis.
Alcohol potentiates the hypotensive effect (reduction of blood pressure) of enalapril, so inform your doctor if you are taking beverages that contain alcohol while taking this medication.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or intend to become pregnant, consult your doctor or pharmacist before using this medication.
Pregnancy
You should inform your doctor if you think you may be pregnant (or could be). Enalapril Tarbis is not recommended at the beginning of pregnancy and should not be taken if you are more than 3 months pregnant, as it can cause serious harm to your baby if used in this stage (see Pregnancy section).
Breastfeeding
Inform your doctor if you are breastfeeding or plan to start breastfeeding. While taking Enalapril Tarbis, it is not recommended to breastfeed newborns (first weeks after birth), and especially premature babies. In the case of an older baby, your doctor should advise you on the benefits and risks of taking Enalapril Tarbis compared to other treatments while breastfeeding.
Driving and operating machinery
Individual responses to medication can vary.
Since Enalapril Tarbis can cause dizziness or fatigue, avoid performing tasks that require special attention (driving vehicles or operating machinery) until you know how you tolerate the medication.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
Enalapril Tarbis 20 mg is administered orally.
Remember to take your medication.
Your doctor will indicate the duration of your treatment with Enalapril Tarbis. Do not discontinue treatment before.
Enalapril Tarbis can be taken with meals or between them along with a glass of water.
Your doctor will decide on the appropriate dose of Enalapril Tarbis you should take, depending on your condition and if you are taking other medications.
The recommended dose is:
Hypertension
For most patients, the initial recommended dose is usually 5 to 20 mg once a day. Some patients may need a lower initial dose.
The usual long-term dose is 20 mg once a day.
Heart Failure
The initial recommended dose is usually 2.5 mg once a day. The doctor will gradually increase the dose until the appropriate dose is reached in your case. The usual long-term dose is 20 mg per day in one or two doses.
Caution should be exercised at the beginning of treatment due to the possibility of dizziness or vertigo appearing.
Inform your doctor immediately if you experience these symptoms.
If you estimate that the action of Enalapril Tarbis 20 mg is too strong or too weak, inform your doctor or pharmacist.
If you take more Enalapril Tarbis than you should
If you take more Enalapril Tarbis than you should, consult your doctor or pharmacist immediately.
In case of an overdose, the most likely symptom is a feeling of dizziness or vertigo due to a sudden or excessive drop in blood pressure.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medication and the amount ingested.
If you forgot to take Enalapril Tarbis
You should continue taking Enalapril Tarbis as prescribed. Do not take a double dose to compensate for the missed doses.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, Enalapril Tarbis may cause side effects, although not everyone will experience them.
Side effects have been classified according to the following definitions of frequencies:
Very common (may affect more than 1 in 10 patients); common (may affect up to 1 in 10 patients); uncommon (may affect up to 1 in 100 patients); rare (may affect up to 1 in 1,000 patients); very rare (may affect up to 1 in 10,000 patients); frequency not known (cannot be estimated from available data).
Blood and lymphatic system disorders:
Uncommon:anemia (decrease in the number of red blood cells in the blood) (including aplastic and hemolytic anemia).
Rare:blood disorders, such as an abnormally low number of neutrophils (a type of blood cell), low hemoglobin levels, reduction or complete absence of granulocytes (a type of blood cell), deficiency of all blood cells, bone marrow depression (tissue inside the bone that generates blood cells), lymph node disease or abnormal immune response.
Metabolism and nutrition disorders:
Uncommon:low blood glucose levels (hypoglycemia).
Nervous system and mental disorders:
Common:headache, depression.
Uncommon:confusion, drowsiness or inability to sleep, nervousness, sensation of tingling or numbness, dizziness.
Rare:sleep disturbances, sleep disorders.
Eye disorders:
Very common:blurred vision.
Cardiac and vascular disorders:
Very common:dizziness.
Common:fall in blood pressure (including orthostatic hypotension), fainting, chest pain, cardiac rhythm disturbances, angina pectoris, rapid heartbeats.
Uncommon:orthostatic hypotension (decrease in blood pressure when sitting or standing), rapid and strong heartbeats, possible myocardial infarction or stroke due to excessively low blood pressure in high-risk patients (patients with alterations in blood flow to the heart and/or brain).
Rare:small arteries, usually in the fingers or toes, that produce spasms causing the skin to become pale or red and blue (Raynaud's phenomenon).
Respiratory, thoracic and mediastinal disorders:
Very common:cough.
Common:difficulty breathing.
Uncommon:nasal mucus discharge, sore throat and hoarseness, asthma.
Rare:fluid in the lungs, inflammation of the nasal mucosa membrane, allergic inflammation of the lungs.
Gastrointestinal disorders:
Very common:nausea.
Common:diarrhea, abdominal pain, altered taste.
Uncommon:intestinal obstruction, pancreatitis, vomiting, indigestion, constipation, anorexia, gastric irritation, dry mouth, peptic ulcer.
Rare:inflammation and ulcers of the mouth, inflammation of the tongue.
Very rare:intestinal angioedema (swelling in the intestine).
Hepatobiliary disorders:
Rare:liver insufficiency, hepatitis, reduction or obstruction of bile flow from the bile duct to the liver (cholestasis) including yellowing of the skin (jaundice).
Skin and subcutaneous tissue disorders:
Common:skin rash, hypersensitivity or allergic reaction causing swelling of the face, extremities, lips, tongue, glottis, and larynx.
Uncommon:sweating, pruritus (itching), urticaria (hives), hair loss.
Rare:severe skin reaction, including excessive redness of the skin, blisters, skin peeling.
A complex of symptoms has been observed that may include some of the following reactions:
fever, inflammation of blood vessels, muscle and joint pain, blood disorders affecting blood components and normally detected in a blood test, skin rash, hypersensitivity to sunlight and other skin effects.
Renal and urinary disorders:
Uncommon:reduced kidney function or renal insufficiency, presence of proteins in the urine.
Rare:reduction in the amount of urine produced per day.
Reproductive and mammary disorders:
Uncommon:impotence.
Rare:breast enlargement in men.
General disorders and administration site conditions:
Very common:weakness.
Common:fatigue.
Uncommon:muscle cramps, flushing, ear noises, general malaise, fever.
Investigations:
Common:high potassium levels in the blood, increases in creatinine in the blood.
Uncommon:increases in urea in the blood, decrease in sodium levels in the blood.
Rare:increases in liver enzymes, increases in bilirubin in the blood.
Stop taking Enalapril Tarbis and consult your doctor immediately in any of the following cases:
You should be aware that black patients are more sensitive to this type of adverse reaction.
Reporting of side effects:
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the Spanish System for the Vigilance of Medicines for Human Use, Website:www.notificaRAM.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep Enalapril Tarbis 20 mg out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the packaging after CAD. The expiration date is the last day of the month indicated.
No special storage conditions are required.
Medicines should not be disposed of through drains or in the trash. Dispose of the packaging and medicines you no longer need at the SIGRE collection point of the pharmacy. If in doubt, ask your pharmacist how to dispose of the packaging and medicines you no longer need. By doing so, you will help protect the environment.
Composition of Enalapril Tarbis
Appearance of the product and contents of the packaging
Enalapril Tarbis is presented in the form of white, biconvex, scored tablets. Each package contains 28 tablets.
Holder of the marketing authorization and responsible manufacturer
Holder of the marketing authorization:
TARBIS FARMA, S.L.
Gran Vía Carlos III, 94
08028 Barcelona
Responsible manufacturer:
Laboratorios Medicamentos Internacionales, S.A.
Solana, 26
28850 Torrejón de Ardoz (Madrid), Spain
or
FERRER INTERNACIONAL, S.A.
Joan Buscallà, 1-9
08173 Sant Cugat del Vallès (Barcelona), Spain
Last review date of this leaflet: May 2019
The detailed and updated information on this medication is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS) http://www.aemps.gob.es/
Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.